GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » Cash Flow from Financing

Cormedix (Cormedix) Cash Flow from Financing : $48.62 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cormedix Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Cormedix paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Cormedix spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.


Cormedix Cash Flow from Financing Historical Data

The historical data trend for Cormedix's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Cash Flow from Financing Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.80 40.10 41.76 17.90 55.92

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.20 5.35 42.90 0.47 -0.10

Cormedix Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Cormedix's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Cormedix's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cormedix  (NAS:CRMD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Cormedix's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Cormedix's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Cormedix's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Cormedix received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Cormedix's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Cormedix paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cormedix's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Cormedix received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Cormedix's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Cormedix received $0.00 Mil on other financial activities.


Cormedix Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Cormedix's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (Cormedix) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry officer: Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco director, officer: Chief Executive Officer 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan director C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa director MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart director 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione director ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David officer: EVP, Chief Financial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson officer: EVP, Head of Clinical Ops. 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel officer: EVP, Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan director 44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz director SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan director 700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L. officer: Exec VP of Tech Operations C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch director, officer: Chief Executive Officer 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921